{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T08:35:50Z","timestamp":1778056550012,"version":"3.51.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T00:00:00Z","timestamp":1732147200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T00:00:00Z","timestamp":1732147200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s00228-024-03773-8","type":"journal-article","created":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T04:18:28Z","timestamp":1732162708000},"page":"163-172","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Treatment appropriateness of direct oral anticoagulants in patients with atrial fibrillation for stroke prevention: A real-world prospective study"],"prefix":"10.1007","volume":"81","author":[{"given":"Yeganeh","family":"Pasebani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Rafati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saied","family":"Dalouchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Javad","family":"Bahadori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamed","family":"Ghoshouni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Majid","family":"Haghjoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir Farjam","family":"Fazelifar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abolfath","family":"Alizadeh\u2010Diz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shabnam","family":"Madadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farzad","family":"Kamali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naser","family":"Hadavand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azita H","family":"Talasaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory Y. H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zahra","family":"Emkanjoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parham","family":"Sadeghipour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,21]]},"reference":[{"issue":"01","key":"3773_CR1","doi-asserted-by":"publisher","first-page":"020","DOI":"10.1055\/s-0041-1739411","volume":"122","author":"T-F Chao","year":"2022","unstructured":"Chao T-F, Joung B, Takahashi Y, Lim TW, Choi E-K, Chan Y-H et al (2022) 2021 focused update consensus guidelines of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation: executive summary. Thromb Haemost 122(01):020\u2013047","journal-title":"Thromb Haemost"},{"key":"3773_CR2","doi-asserted-by":"publisher","unstructured":"Wang Y, Guo Y, Qin M, Fan J, Tang M, Zhang X et al (2024) Chinese expert consensus guidelines on the diagnosis and treatment of atrial fibrillation in the elderly. Executive summary. Thromb Haemost. https:\/\/doi.org\/10.1055\/a-2325-5923","DOI":"10.1055\/a-2325-5923"},{"issue":"2","key":"3773_CR3","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1177\/1074248417731536","volume":"23","author":"H Elewa","year":"2018","unstructured":"Elewa H, El-Makaty H, Ali Z (2018) Appropriateness of dabigatran and rivaroxaban prescribing in Qatar: a 5-year experience. J Cardiovasc Pharmacol Ther 23(2):155\u2013161","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"10","key":"3773_CR4","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1093\/europace\/euab065","volume":"23","author":"J Steffel","year":"2021","unstructured":"Steffel J, Collins R, Antz M, Cornu P, Desteghe L, Haeusler KG et al (2021) 2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. EP Europace 23(10):1612\u20131676","journal-title":"EP Europace"},{"issue":"2","key":"3773_CR5","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1111\/bcp.15017","volume":"88","author":"S Moudallel","year":"2022","unstructured":"Moudallel S, Cornu P, Dupont A, Steurbaut S (2022) Determinants for under-and overdosing of direct oral anticoagulants and physicians\u2019 implementation of clinical pharmacists\u2019 recommendations. Br J Clin Pharmacol 88(2):753\u2013763","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"3773_CR6","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1007\/s00228-022-03286-2","volume":"78","author":"A Carbone","year":"2022","unstructured":"Carbone A, Santelli F, Bottino R, Attena E, Mazzone C, Parisi V et al (2022) Prevalence and clinical predictors of inappropriate direct oral anticoagulant dosage in octagenarians with atrial fibrillation. Eur J Clin Pharmacol 78(5):879\u2013886","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"3773_CR7","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.014108","volume":"9","author":"S Sanghai","year":"2020","unstructured":"Sanghai S, Wong C, Wang Z, Clive P, Tran W, Waring M et al (2020) Rates of potentially inappropriate dosing of direct-acting oral anticoagulants and associations with geriatric conditions among older patients with atrial fibrillation: the SAGE-AF study. J Am Heart Assoc 9(6):e014108","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"3773_CR8","doi-asserted-by":"publisher","first-page":"e2317156-e","DOI":"10.1001\/jamanetworkopen.2023.17156","volume":"6","author":"JA Rymer","year":"2023","unstructured":"Rymer JA, Chiswell K, Young L, Chiu A, Liu L, Webb L et al (2023) Analysis of oral anticoagulant dosing and adherence to therapy among patients with nonvalvular atrial fibrillation. JAMA Network Open 6(6):e2317156-e","journal-title":"JAMA Network Open"},{"issue":"24","key":"3773_CR9","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1016\/j.jacc.2016.09.966","volume":"68","author":"BA Steinberg","year":"2016","unstructured":"Steinberg BA, Shrader P, Thomas L, Ansell J, Fonarow GC, Gersh BJ et al (2016) Off-label dosing of non-vitamin K antagonist oral anticoagulants and adverse outcomes: the ORBIT-AF II registry. J Am Coll Cardiol 68(24):2597\u20132604","journal-title":"J Am Coll Cardiol"},{"issue":"23","key":"3773_CR10","doi-asserted-by":"publisher","first-page":"2779","DOI":"10.1016\/j.jacc.2017.03.600","volume":"69","author":"X Yao","year":"2017","unstructured":"Yao X, Shah ND, Sangaralingham LR, Gersh BJ, Noseworthy PA (2017) Non\u2013vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction. J Am Coll Cardiol 69(23):2779\u20132790","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"3773_CR11","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1016\/j.jacc.2020.07.045","volume":"76","author":"AJ Camm","year":"2020","unstructured":"Camm AJ, Cools F, Virdone S, Bassand J-P, Fitzmaurice DA, Arthur Fox KA et al (2020) Mortality in patients with atrial fibrillation receiving nonrecommended doses of direct oral anticoagulants. J Am Coll Cardiol 76(12):1425\u20131436","journal-title":"J Am Coll Cardiol"},{"issue":"9596","key":"3773_CR12","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","volume":"370","author":"E Von Elm","year":"2007","unstructured":"Von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP (2007) The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. The Lancet 370(9596):1453\u20131457","journal-title":"The Lancet"},{"issue":"16","key":"3773_CR13","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","volume":"39","author":"J Steffel","year":"2018","unstructured":"Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L et al (2018) The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 39(16):1330\u20131393","journal-title":"Eur Heart J"},{"issue":"5","key":"3773_CR14","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"G Hindricks","year":"2020","unstructured":"Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstr\u00f6m-Lundqvist C et al (2020) 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 42(5):373\u2013498","journal-title":"Eur Heart J"},{"issue":"11","key":"3773_CR15","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1111\/jth.13140","volume":"13","author":"S Kaatz","year":"2015","unstructured":"Kaatz S, Ahmad D, Spyropoulos A, Schulman S (2015) Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost 13(11):2119\u20132126","journal-title":"J Thromb Haemost"},{"issue":"10","key":"3773_CR16","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1093\/europace\/eux316","volume":"20","author":"M Ruiz Ortiz","year":"2018","unstructured":"Ruiz Ortiz M, Mu\u00f1iz J, Ra\u00f1a M\u00edguez P, Rold\u00e1n I, Mar\u00edn F, Asunci\u00f3n Esteve-Pastor M et al (2018) Inappropriate doses of direct oral anticoagulants in real-world clinical practice: prevalence and associated factors. A subanalysis of the FANTASIIA Registry. Ep Europace 20(10):1577\u20131583","journal-title":"Ep Europace"},{"issue":"703","key":"3773_CR17","doi-asserted-by":"publisher","first-page":"e134","DOI":"10.3399\/bjgp20X714005","volume":"71","author":"E Ferrat","year":"2021","unstructured":"Ferrat E, Fabre J, Galletout P, Boutin E, Le Breton J, Renard V et al (2021) Inappropriate direct oral anticoagulant prescriptions in patients with non-valvular atrial fibrillation: cross-sectional analysis of the French CACAO cohort study in primary care. Br J Gen Pract 71(703):e134\u2013e139","journal-title":"Br J Gen Pract"},{"issue":"4","key":"3773_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0214666","volume":"14","author":"S Han","year":"2019","unstructured":"Han S, Jeong HS, Kim H, Suh HS (2019) The treatment pattern and adherence to direct oral anticoagulants in patients with atrial fibrillation aged over 65. PLoS ONE 14(4):e0214666","journal-title":"PLoS ONE"},{"key":"3773_CR19","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.amjcard.2020.09.053","volume":"139","author":"J Ohno","year":"2021","unstructured":"Ohno J, Sotomi Y, Hirata A, Sakata Y, Hirayama A, Higuchi Y (2021) Dose of direct oral anticoagulants and adverse outcomes in Asia. Am J Cardiol 139:50\u201356","journal-title":"Am J Cardiol"},{"key":"3773_CR20","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.amjcard.2020.12.062","volume":"144","author":"A Sugrue","year":"2021","unstructured":"Sugrue A, Sanborn D, Amin M, Farwati M, Sridhar H, Ahmed A et al (2021) Inappropriate dosing of direct oral anticoagulants in patients with atrial fibrillation. Am J Cardiol 144:52\u201359","journal-title":"Am J Cardiol"},{"key":"3773_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.581293","volume":"12","author":"N-N Shen","year":"2021","unstructured":"Shen N-N, Zhang C, Hang Y, Li Z, Kong L-C, Wang N et al (2021) Real-world prevalence of direct oral anticoagulant off-label doses in atrial fibrillation: an epidemiological meta-analysis. Front Pharmacol 12:581293","journal-title":"Front Pharmacol"},{"issue":"6","key":"3773_CR22","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1097\/MAJ.0000000000000349","volume":"348","author":"S Sen","year":"2014","unstructured":"Sen S, Dahlberg KW (2014) Physician\u2019s fear of anticoagulant therapy in nonvalvular atrial fibrillation. Am J Med Sci 348(6):513\u2013521","journal-title":"Am J Med Sci"},{"key":"3773_CR23","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.ijcard.2017.07.012","volume":"249","author":"M Ding","year":"2017","unstructured":"Ding M, Fratiglioni L, Johnell K, Fastbom J, Ljungdahl M, Qiu C (2017) Atrial fibrillation and use of antithrombotic medications in older people: a population-based study. Int J Cardiol 249:173\u2013178","journal-title":"Int J Cardiol"},{"issue":"6","key":"3773_CR24","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.cjca.2015.09.023","volume":"32","author":"JG Andrade","year":"2016","unstructured":"Andrade JG, Krahn AD, Skanes AC, Purdham D, Ciaccia A, Connors S (2016) Values and preferences of physicians and patients with nonvalvular atrial fibrillation who receive oral anticoagulation therapy for stroke prevention. Can J Cardiol 32(6):747\u2013753","journal-title":"Can J Cardiol"},{"key":"3773_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40780-020-0157-z","volume":"6","author":"M Miyazaki","year":"2020","unstructured":"Miyazaki M, Matsuo K, Uchiyama M, Nakamura Y, Sakamoto Y, Misaki M et al (2020) Inappropriate direct oral anticoagulant dosing in atrial fibrillation patients is associated with prescriptions for outpatients rather than inpatients: a single-center retrospective cohort study. Journal of Pharmaceutical Health Care and Sciences 6:1\u201311","journal-title":"Journal of Pharmaceutical Health Care and Sciences"},{"issue":"09","key":"3773_CR26","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1055\/a-1789-4824","volume":"122","author":"E Ivany","year":"2022","unstructured":"Ivany E, Lotto RR, Lip GY, Lane DA (2022) Managing uncertainty: physicians\u2019 decision making for stroke prevention for patients with atrial fibrillation and intracerebral hemorrhage. Thromb Haemost 122(09):1603\u20131611","journal-title":"Thromb Haemost"},{"issue":"11","key":"3773_CR27","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.020697","volume":"10","author":"JA Rymer","year":"2021","unstructured":"Rymer JA, Webb L, McCall D, Hills MT, Wang TY (2021) Differences in preferences between clinicians and patients for the use and dosing of direct oral anticoagulants for atrial fibrillation. J Am Heart Assoc 10(11):e020697","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"3773_CR28","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1001\/jamacardio.2015.0382","volume":"1","author":"JP Piccini Sr","year":"2016","unstructured":"Piccini JP Sr, Fonarow GC (2016) Preventing stroke in patients with atrial fibrillation\u2014a steep climb away from achieving peak performance. JAMA Cardiology 1(1):63\u201364","journal-title":"JAMA Cardiology"},{"issue":"9921","key":"3773_CR29","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","volume":"383","author":"CT Ruff","year":"2014","unstructured":"Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD et al (2014) Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. The Lancet 383(9921):955\u2013962","journal-title":"The Lancet"},{"issue":"10","key":"3773_CR30","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1055\/s-0042-1750385","volume":"122","author":"DA Gorog","year":"2022","unstructured":"Gorog DA, Gue YX, Chao T-F, Fauchier L, Ferreiro JL, Huber K et al (2022) Assessment and mitigation of bleeding risk in atrial fibrillation and venous thromboembolism: executive summary of a European and Asia-Pacific expert consensus paper. Thromb Haemost 122(10):1625\u20131652","journal-title":"Thromb Haemost"},{"issue":"4","key":"3773_CR31","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.jacc.2007.01.098","volume":"50","author":"AY-J Shen","year":"2007","unstructured":"Shen AY-J, Yao JF, Brar SS, Jorgensen MB, Chen W (2007) Racial\/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation. Journal of the American College of Cardiology. 50(4):309\u2013315","journal-title":"Journal of the American College of Cardiology."},{"issue":"2","key":"3773_CR32","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1093\/eurheartj\/ehad508","volume":"45","author":"H Buhari","year":"2023","unstructured":"Buhari H, Fang J, Han L, Austin PC, Dorian P, Jackevicius CA et al (2023) Stroke risk in women with atrial fibrillation. Eur Heart J 45(2):104\u2013113","journal-title":"Eur Heart J"},{"issue":"2","key":"3773_CR33","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.annemergmed.2022.03.010","volume":"80","author":"S Islam","year":"2022","unstructured":"Islam S, Dover DC, Daniele P, Hawkins NM, Humphries KH, Kaul P et al (2022) Sex differences in the management of oral anticoagulation and outcomes for emergency department presentation of incident atrial fibrillation. Ann Emerg Med 80(2):97\u2013107","journal-title":"Ann Emerg Med"},{"issue":"12","key":"3773_CR34","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1016\/j.jacc.2010.12.013","volume":"57","author":"R Marinigh","year":"2011","unstructured":"Marinigh R, Lane DA, Lip GYH (2011) Severe renal impairment and stroke prevention in atrial fibrillation: implications for thromboprophylaxis and bleeding risk. J Am Coll Cardiol 57(12):1339\u20131348","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"3773_CR35","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1055\/s-0042-1756355","volume":"122","author":"GF Romiti","year":"2022","unstructured":"Romiti GF, Proietti M, Bonini N, Ding WY, Boriani G, Huisman MV et al (2022) Clinical complexity domains, anticoagulation, and outcomes in patients with atrial fibrillation: a report from the GLORIA-AF registry phase II and III. Thromb Haemost 122(12):2030\u20132041","journal-title":"Thromb Haemost"},{"issue":"02","key":"3773_CR36","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1055\/s-0043-1769735","volume":"124","author":"M Grymonprez","year":"2024","unstructured":"Grymonprez M, Petrovic M, De Backer TL, Steurbaut S, Lahousse L (2024) The impact of polypharmacy on the effectiveness and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Thromb Haemost 124(02):135\u2013148","journal-title":"Thromb Haemost"},{"key":"3773_CR37","doi-asserted-by":"publisher","unstructured":"Zheng Y, Li S, Liu X, Lip GY, Guo L, Zhu W. (2023) Effect of oral anticoagulants in atrial fibrillation patients with polypharmacy: a meta-analysis. Thrombosis and Haemostasis. https:\/\/doi.org\/10.1055\/s-0043-1770724","DOI":"10.1055\/s-0043-1770724"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-024-03773-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-024-03773-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-024-03773-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T07:15:26Z","timestamp":1735802126000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-024-03773-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,21]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["3773"],"URL":"https:\/\/doi.org\/10.1007\/s00228-024-03773-8","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,21]]},"assertion":[{"value":"16 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Lip is a consultant and speaker for BMS\/Pfizer, Boehringer Ingelheim, Daiichi-Sankyo, Anthos. No fees are received personally.\u00a0 He is a National Institute for Health and Care Research (NIHR) Senior Investigator and co-principal investigator of the AFFIRMO project on multi morbidity in AF, which has received funding from the European Union\u2019s Horizon 2020 research and innovation program me under grant agreement No 899871.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}